{"id": 883048658744340482, "lang": "en", "text": "@US_FDA will continue to examine the risk-benefit of all approved opioid analgesic products and take further action\u2026 https://t.co/ryvEAJUlxX", "urls": [{"url": "https://t.co/ryvEAJUlxX", "expanded_url": "https://twitter.com/i/web/status/883048658744340482"}], "user": {"id": 44783853}, "id_str": "883048658744340482", "source": "<a href=\"https://sproutsocial.com\" rel=\"nofollow\">Sprout Social</a>", "deleted": false, "hashtags": [], "retrieved": "2018-09-27--06-45-04", "truncated": true, "created_at": "Thu Jul 06 19:43:01 +0000 2017", "retweet_count": 7, "user_mentions": [{"id": 208120290, "name": "U.S. FDA", "screen_name": "US_FDA"}], "favorite_count": 5, "legacy_imported": true, "in_reply_to_user_id": 208120290, "in_reply_to_screen_name": "US_FDA"}